Detecting myositis as a cause of unexplained dysphagia: Proposal for a diagnostic algorithm.


Journal

European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311

Informations de publication

Date de publication:
04 2022
Historique:
revised: 21 11 2021
received: 28 07 2021
accepted: 01 12 2021
pubmed: 5 12 2021
medline: 5 4 2022
entrez: 4 12 2021
Statut: ppublish

Résumé

Idiopathic inflammatory myopathy (IIM) can present with dysphagia as a leading or only symptom. In such cases, diagnostic evaluation may be difficult, especially if serological and electromyographical findings are unsuspicious. In this observational study we propose and evaluate a diagnostic algorithm to identify IIM as a cause of unexplained dysphagia. Over a period of 4 years, patients with unexplained dysphagia were offered diagnostic evaluation according to a specific algorithm: The pattern of dysphagia was characterized by instrumental assessment (swallowing endoscopy, videofluoroscopy, high-resolution manometry). Patients with an IIM-compatible dysphagia pattern were subjected to further IIM-focused diagnostic procedures, including whole-body muscle magnetic resonance imaging, electromyography, creatine kinase blood level, IIM antibody panel and, as a final diagnostic step, muscle biopsy. Muscle biopsies were taken from affected muscles. In cases where no other muscles showed abnormalities, the cricopharyngeal muscle was targeted. Seventy-two patients presented with IIM-compatible dysphagia as a leading or only symptom. As a result of the specific diagnostic approach, 19 of these patients were diagnosed with IIM according to the European League Against Rheumatism (EULAR) criteria. Eighteen patients received immunomodulatory therapy as a result of the diagnosis. Of 10 patients with follow-up swallowing examination, dysphagia improved in three patients after therapy, while it remained at least stable in six patients. Idiopathic inflammatory myopathy constitutes a potentially treatable etiology in patients with unexplained dysphagia. The diagnostic algorithm presented in this study helps to identify patients with an IIM-compatible dysphagia pattern and to assign those patients for further IIM-focused diagnostic and therapeutic procedures.

Sections du résumé

BACKGROUND AND PURPOSE
Idiopathic inflammatory myopathy (IIM) can present with dysphagia as a leading or only symptom. In such cases, diagnostic evaluation may be difficult, especially if serological and electromyographical findings are unsuspicious. In this observational study we propose and evaluate a diagnostic algorithm to identify IIM as a cause of unexplained dysphagia.
METHODS
Over a period of 4 years, patients with unexplained dysphagia were offered diagnostic evaluation according to a specific algorithm: The pattern of dysphagia was characterized by instrumental assessment (swallowing endoscopy, videofluoroscopy, high-resolution manometry). Patients with an IIM-compatible dysphagia pattern were subjected to further IIM-focused diagnostic procedures, including whole-body muscle magnetic resonance imaging, electromyography, creatine kinase blood level, IIM antibody panel and, as a final diagnostic step, muscle biopsy. Muscle biopsies were taken from affected muscles. In cases where no other muscles showed abnormalities, the cricopharyngeal muscle was targeted.
RESULTS
Seventy-two patients presented with IIM-compatible dysphagia as a leading or only symptom. As a result of the specific diagnostic approach, 19 of these patients were diagnosed with IIM according to the European League Against Rheumatism (EULAR) criteria. Eighteen patients received immunomodulatory therapy as a result of the diagnosis. Of 10 patients with follow-up swallowing examination, dysphagia improved in three patients after therapy, while it remained at least stable in six patients.
CONCLUSIONS
Idiopathic inflammatory myopathy constitutes a potentially treatable etiology in patients with unexplained dysphagia. The diagnostic algorithm presented in this study helps to identify patients with an IIM-compatible dysphagia pattern and to assign those patients for further IIM-focused diagnostic and therapeutic procedures.

Identifiants

pubmed: 34862828
doi: 10.1111/ene.15202
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1165-1173

Informations de copyright

© 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Références

Jean A. Brain stem control of swallowing: neuronal network and cellular mechanisms. Physiol Rev. 2001;81(2):929-969.
Miller AJ. The neurobiology of swallowing and dysphagia. Dev Disabil Res Rev. 2008;14(2):77-86.
Labeit B, Muhle P, Ogawa M, et al. FEES-based assessment of pharyngeal hypesthesia-proposal and validation of a new test procedure. Neurogastroenterol Motil. 2019;31(11):e13690.
Warnecke T, Labeit B, Schroeder J, et al. Neurogenic dysphagia: systematic review and proposal of a classification system. Neurology. 2021;96(6):e876-e889.
Labeit B, Mueller H, Muhle P, et al. Predicting dysphagia with national institute of health stroke scale: distinction between infra- and supratentorial region is essential. Cerebrovasc Dis. 2018;46(3-4):152-160.
Suttrup I, Warnecke T. Dysphagia in Parkinson's disease. Dysphagia. 2016;31(1):24-32.
Seçil Y, Arıcı Ş, İncesu TK, Gürgör N, Beckmann Y, Ertekin C. Dysphagia in Alzheimer's disease. Neurophysiol Clin. 2016;46(3):171-178.
Onesti E, Schettino I, Gori MC, et al. Dysphagia in amyotrophic lateral sclerosis: impact on patient behavior, diet adaptation, and riluzole management. Front Neurol. 2017;8:94.
Calcagno P, Ruoppolo G, Grasso MG, de Vincentiis M, Paolucci S. Dysphagia in multiple sclerosis-prevalence and prognostic factors. Acta Neurol Scand. 2002;105(1):40-43.
Pawlitzki M, Ahring S, Rolfes L, et al. Dysphagia in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody disease as a surrogate of brain involvement? Eur J Neurol. 2021;28(5):1765-1770.
Labeit B, Pawlitzki M, Ruck T, et al. The impact of dysphagia in myositis: a systematic review and meta-analysis. J Clin Med. 2020;9(7):2150.
Higo R, Nito T, Tayama N. Videofluoroscopic assessment of swallowing function in patients with myasthenia gravis. J Neurol Sci. 2005;231(1-2):45-48.
Warnecke T, Im S, Labeit B, et al. Detecting myasthenia gravis as a cause of unclear dysphagia with an endoscopic tensilon test. Ther Adv Neurol Disord. 2021;14:17562864211035544.
Buchholz DW. Neurogenic dysphagia: what is the cause when the cause is not obvious? Dysphagia. 1994;9(4):245-255.
Bottai M, Tjarnlund A, Santoni G, et al. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open. 2017;3(2):e000507.
Oh TH, Brumfield KA, Hoskin TL, Kasperbauer JL, Basford JR. Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome. Am J Phys Med Rehabil. 2008;87(11):883-889.
Williams RB, Grehan MJ, Hersch M, Andre J, Cook IJ. Biomechanics, diagnosis, and treatment outcome in inflammatory myopathy presenting as oropharyngeal dysphagia. Gut. 2003;52(4):471-478.
Peng A, Koffman BM, Malley JD, Dalakas MC. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology. 2000;55(2):296-298.
Labeit B, Muhle P, Suntrup-Krueger S, et al. Dysphagia as isolated manifestation of Jo-1 associated myositis? Front Neurol. 2019;10:739. 10.3389/fneur.2019.00739
Labeit B, Ahring S, Boehmer M, et al. Comparison of simultaneous swallowing endoscopy and videofluoroscopy in neurogenic dysphagia. J Am Med Dir Assoc. 2021;S1525-8610(21)00862-8. https://doi.org/10.1016/j.jamda.2021.09.026
Murata K-Y, Kouda K, Tajima F, Kondo T. A dysphagia study in patients with sporadic inclusion body myositis (s-IBM). Neurol Sci. 2012;33(4):765-770.
Olthoff A, Carstens P-O, Zhang S, et al. Evaluation of dysphagia by novel real-time MRI. Neurology. 2016;87(20):2132-2138.
Cox FM, Verschuuren JJ, Verbist BM, Niks EH, Wintzen AR, Badrising UA. Detecting dysphagia in inclusion body myositis. J Neurol. 2009;256(12):2009-2013.
Langdon PC, Mulcahy K, Shepherd KL, Low VH, Mastaglia FL. Pharyngeal dysphagia in inflammatory muscle diseases resulting from impaired suprahyoid musculature. Dysphagia. 2012;27(3):408-417.
Azola A, Mulheren R, Mckeon G, et al. Dysphagia in myositis: a study of the structural and physiologic changes resulting in disordered swallowing. Am J Phys Med Rehabil. 2020;99(5):404-408.
Labeit B, Perlova K, Pawlitzki M, et al. Predictors, outcome and characteristics of oropharyngeal dysphagia in idiopathic inflammatory myopathy. Muscle Nerve. 2021;63(6):874-880.
Marie I, Menard J-F, Hatron PY, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res (Hoboken). 2010;62(12):1748-1755.
Casal-Dominguez M, Pinal-Fernandez I, Mego M, et al. High-resolution manometry in patients with idiopathic inflammatory myopathy: elevated prevalence of esophageal involvement and differences according to autoantibody status and clinical subset. Muscle Nerve. 2017;56(3):386-392.
Crary MA, Mann GDC, Groher ME. Initial psychometric assessment of a functional oral intake scale for dysphagia in stroke patients. Arch Phys Med Rehabil. 2005;86(8):1516-1520.
Warnecke T, Teismann I, Zimmermann J, Oelenberg S, Ringelstein EB, Dziewas R. Fiberoptic endoscopic evaluation of swallowing with simultaneous Tensilon application in diagnosis and therapy of myasthenia gravis. J Neurol. 2008;255(2):224-230.
McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018;14(5):290-302.
Pluk H, van Hoeve BJA, van Dooren SHJ, et al. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013;73(3):397-407.
Langmore SE. Endoscopic Evaluation and Treatment of Swallowing Disorders. Thieme; 2001.
Kornblum C, Broicher R, Walther E, et al. Cricopharyngeal achalasia is a common cause of dysphagia in patients with mtDNA deletions. Neurology. 2001;56(10):1409-1412.
Horvath OP, Zombori J, Halmos L, Bozoky B, Olah T. Pharyngeal dysphagia caused by isolated myogen dystrophy of musculus cricopharyngeus. Acta Chir Hung. 1998;37(1-2):51-58.
Eura N, Sugie K, Kiriyama T, Ueno S. Characteristic dysphagia as a manifestation of dermatomyositis on oropharyngeal muscle imaging. J Clin Rheumatol. 2015;21(2):105-106.
Otao G, Yamashita S-I, Kyoraku I, Shiomi K, Nakazato M. Dysphagia due to inflammation of oral muscles as the first symptom of dermatomyositis. Intern Med. 2007;46(12):923-924.
Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991;325(21):1487-1498.
Malik A, Hayat G, Kalia JS, Guzman MA. Idiopathic inflammatory myopathies: clinical approach and management. Front Neurol. 2016;7:64.
Riminton DS, Chambers ST, Parkin PJ, Pollock M, Donaldson IM. Inclusion body myositis presenting solely as dysphagia. Neurology. 1993;43(6):1241-1243.
Shapiro J, Martin S, DeGirolami U, Goyal R. Inflammatory myopathy causing pharyngeal dysphagia: a new entity. Ann Otol Rhinol Laryngol. 1996;105(5):331-335.
Devic P, Gallay L, Streichenberger N, Petiot P. Focal myositis: a review. Neuromuscul Disord. 2016;26(11):725-733.
Lynn SJ, Sawyers SM, Moller PW, O'Donnell JL, Chapman PT. Adult-onset inflammatory myopathy: north Canterbury experience 1989-2001. Intern Med J. 2005;35(3):170-173.
Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology. 2002;58(2):326.
Ko EH, Rubin AD. Dysphagia due to inclusion body myositis: case presentation and review of the literature. Ann Otol Rhinol Laryngol. 2014;123(9):605-608.
Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997;48(3):712-716.
Singh S, Hamdy S. The upper oesophageal sphincter. Neurogastroenterol Motil. 2005;17(Suppl 1):3-12.
Sivarao DV, Goyal RK. Functional anatomy and physiology of the upper esophageal sphincter. Am J Med. 2000;108(Suppl 4a):27S-37S.
Bachmann G, Streppel M, Krug B, Neuen-Jacob E. Cricopharyngeal muscle hypertrophy associated with florid myositis. Dysphagia. 2001;16(4):244-248.
Murata K-Y, Kouda K, Tajima F, Kondo T. Balloon dilation in sporadic inclusion body myositis patients with dysphagia. Clin Med Insights Case Rep. 2013;6:1-7.
Liu LWC, Tarnopolsky M, Armstrong D. Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis. Can J Gastroenterol. 2004;18(6):397-399.
Schrey A, Airas L, Jokela M, Pulkkinen J. Botulinum toxin alleviates dysphagia of patients with inclusion body myositis. J Neurol Sci. 2017;380:142-147.

Auteurs

Bendix Labeit (B)

Department of Neurology with Institute of Translational Neurology, University of Muenster, Muenster, Germany.
Institute for Biomagnetism and Biosignal Analysis, University of Muenster, Muenster, Germany.

Thalia Grond (T)

Department of Neurology with Institute of Translational Neurology, University of Muenster, Muenster, Germany.

Achim G Beule (AG)

Department of Otorhinolaryngology, Head and Neck Surgery, University of Muenster, Muenster, Germany.

Maik Boehmer (M)

Institute of Clinical Radiology, University of Muenster, Muenster, Germany.

Christian Thomas (C)

Institute of Neuropathology, University of Muenster, Muenster, Germany.

Paul Muhle (P)

Department of Neurology with Institute of Translational Neurology, University of Muenster, Muenster, Germany.
Institute for Biomagnetism and Biosignal Analysis, University of Muenster, Muenster, Germany.

Inga Claus (I)

Department of Neurology with Institute of Translational Neurology, University of Muenster, Muenster, Germany.

Malte Roderigo (M)

Department of Neurology with Institute of Translational Neurology, University of Muenster, Muenster, Germany.

Claudia Rudack (C)

Department of Otorhinolaryngology, Head and Neck Surgery, University of Muenster, Muenster, Germany.

Heinz Wiendl (H)

Department of Neurology with Institute of Translational Neurology, University of Muenster, Muenster, Germany.

Rainer Dziewas (R)

Department of Neurology and Neurorehabilitation, Hospital Osnabrueck, Osnabrueck, Germany.

Tobias Warnecke (T)

Department of Neurology with Institute of Translational Neurology, University of Muenster, Muenster, Germany.

Sonja Suntrup-Krueger (S)

Department of Neurology with Institute of Translational Neurology, University of Muenster, Muenster, Germany.
Institute for Biomagnetism and Biosignal Analysis, University of Muenster, Muenster, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH